MBOTMBOTHealthcare · Medical Devices

MBOT Stock Forecast: Microbot Medical, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.68
−8.11% on the day

The median 12-month analyst price target for Microbot Medical, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 15 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$49.7M
Ticker Nerd rank
15/ 100
Median analyst target
$3.00
Analysts covering
4
Revenue$105K
Operating income−$4.3M
Net income−$3.7M
Free cash flow−$5.2M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−30.6%
1M
−28.4%
YTD
−66.0%
1Y
−60.7%
From 52W high
−76.1%
From 52W low
+6.3%
$0.64
$2.85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Microbot Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
15/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
43
Revisions
39
Issuance
38
Quality
35
Volatility
32
Growth
30
Value
8
Momentum
8

Accruals (43): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MBOT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MBOT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26MBOTHigh $12.00Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$2.00
Low
$3.00
Median
$12.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
19 Nov 2026B. Riley SecuritiesMaintainsBuy$4.00 → $3.00
17 Nov 2026CitizensMaintainsMarket Outperform$2.50 → $2.00
23 Oct 2026CitizensInitiatesMarket Outperform$2.50
21 Oct 2026HC Wainwright & Co.ReiteratesBuy$12
14 Aug 2026B. Riley SecuritiesReiteratesBuy$5.00 → $4.00
3 June 2026LUCID CAPITAL MARKETSInitiatesBuy$4.00
14 Apr 2026HC Wainwright & Co.ReiteratesBuy—
10 Feb 2026B. Riley SecuritiesInitiatesBuy—
3 Dec 2025Roth CapitalInitiatesBuy—
28 Nov 2025HC Wainwright & Co.ReiteratesBuy—
15 Oct 2025HC Wainwright & Co.ReiteratesBuy—
11 Sept 2025HC Wainwright & Co.MaintainsBuy—
10 Apr 2025HC Wainwright & Co.ReiteratesBuy—
24 Jan 2025HC Wainwright & Co.MaintainsBuy—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
16 Apr 2024HC Wainwright & Co.MaintainsBuy—
18 Oct 2023HC Wainwright & Co.ReiteratesBuy—
26 June 2023HC Wainwright & Co.ReiteratesBuy—
6 June 2023HC Wainwright & Co.ReiteratesBuy—
9 May 2023HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MBOT.

Market Radar

This page is one stock. Monday covers all of them.

MBOT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MBOT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Microbot Medical, Inc. returned −60.7% against +6.9% for the S&P 500, dividends included.

MBOT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26MBOTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MBOT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
117.2×

Cheaper than 3% of US stocks

Price / book
0.8×

Cheaper than 78% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
1.9%

Higher than 5% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−26.3%

Higher than 29% of US stocks

Return on assets
−17.6%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Microbot Medical, Inc. has a market value of $49.7M.

  • Revenue in the twelve months to 31 Mar 2026: $105K.

  • Net income over the same four quarters: −$14.2M, a −13535.2% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$15.4M, after $155K of capital spending.

  • Shares outstanding: 67.2M.

  • Microbot Medical, Inc. employs 43 people — $2K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

MBOT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
MBOTMicrobot Medical, Inc.$49.7M15
OMOutset Medical, Inc.$51.4M52
COCHEnvoy Medical, Inc.$51.9M57
ELUTElutia, Inc.$39.9M30
ECORelectroCore, Inc.$39.9M75
LNSRLENSAR, Inc.$54.8M58
SRTSSensus Healthcare, Inc.$37.2M50

Take a look at MBOT’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Microbot Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MBOT

What is the MBOT stock price forecast for 2026-2027?

The median 12-month analyst price target for Microbot Medical, Inc. is $3, with estimates ranging from $2 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MBOT stock a buy right now?

Of the 4 analysts covering Microbot Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Microbot Medical, Inc. 15 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MBOT?

As at 21 Nov 2026, Microbot Medical, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (43 of 100).

Will MBOT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $3, and Ticker Nerd's factor model ranks Microbot Medical, Inc. 15 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MBOT stock forecast for 2030?

No analyst covering Microbot Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBOT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $12 over the next 12 months.

How has MBOT stock performed over the past year?

Microbot Medical, Inc. returned -60.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Microbot Medical, Inc. do?

Microbot Medical Inc. is a medical device company focused on robotic technologies for minimally invasive procedures. Its current product portfolio centers on the LIBERTY Endovascular Robotic System, a disposable robotic platform designed to support catheter-based interventions in cardiovascular, peripheral, endovascular, and neurovascular care.

Company

About Microbot Medical, Inc.

Microbot Medical Inc. is a medical device company focused on robotic technologies for minimally invasive procedures. Its current product portfolio centers on the LIBERTY Endovascular Robotic System, a disposable robotic platform designed to support catheter-based interventions in cardiovascular, peripheral, endovascular, and neurovascular care. The company also works on robotic endoluminal surgery devices aimed at improving precision and control in complex vascular pathways. Microbot Medical Inc. operates in the healthcare technology and medical devices market, where its systems are intended to help clinicians perform procedures with greater remote control and workflow efficiency. Headquartered in Hingham, Massachusetts, the company concentrates on developing specialized tools for interventional medicine and robotic-assisted procedure delivery.

CEO Mr. Harel Gadot · 43 employees · United States · https://microbotmedical.com